Transmedics Announces the World's First Human Liver Transplantation Using the Organ Care System (OCS™) Liver Technology and the Initiation of the OCS™ Liver Protect U.S. Pivotal Trial

Transmedics Announces the World's First Human Liver Transplantation Using the Organ Care System (OCS™) Liver Technology and the Initiation of the OCS™ Liver Protect U.S. Pivotal Trial

February 23, 2016

Andover, Mass., February 23, 2016 -- TransMedics, Inc., the global leader in portable ex-vivo warm perfusion of donor organs for transplantation, announces the world's first human liver transplantation using the OCS™ Liver technology and the initiation of the OCS™ Liver PROTECT Pivotal Trial.

The transplant procedure was performed by Dr. James F. Markmann, Chief of Transplant Surgery at Massachusetts General Hospital. Dr. Markmann is a principal investigator and Chairman of the Steering Committee for the PROTECT Trial.

Oasys Water Continues Expansion of Global Operations to Deliver Treatment Innovation to the Middle East

Oasys Water Continues Expansion of Global Operations to Deliver Treatment Innovation to the Middle East

February 23, 2016

Boston – February 23, 2016 – Oasys Water, the world leader committed to developing innovative Forward Osmosis (FO)-based solutions for transforming complex industrial wastewater streams into valuable freshwater resources, today announced that it has opened an office in Dubai to support business opportunities in the Middle East and Gulf Cooperation Council (GCC) region.

Pronutria Biosciences Announces $42.5 Million Equity Investment from Nestlé Health Science

Pronutria Biosciences Announces $42.5 Million Equity Investment from Nestlé Health Science

February 23, 2016

CAMBRIDGE MA – February 23, 2016 / BUSINESS WIRE / – Pronutria Biosciences Inc., a biotechnology company pioneering first-in-class medicines for serious conditions linked to amino acid imbalances, announced today that it has completed a $42.5 million investment by Nestlé Health Science.

The proceeds from this financing will help to fund the ongoing rapid transformation of the company from a unique and revolutionary platform to late stage clinical candidates in several disease indications.

Agios Reports Fourth Quarter and Full Year 2015 Financial Results and Highlights Key 2016 Milestones

Agios Reports Fourth Quarter and Full Year 2015 Financial Results and Highlights Key 2016 Milestones

February 18, 2016

CAMBRIDGE, Mass., Feb. 18, 2016 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today reported business highlights and financial results for the fourth quarter and year ended December 31, 2015. In addition, Agios highlighted select corporate milestones for its preclinical and clinical development programs.

T2 Biosystems Reports 2015 Fourth Quarter, Full Year Results

T2 Biosystems Reports 2015 Fourth Quarter, Full Year Results

February 16, 2016

LEXINGTON, Mass., Feb. 16, 2016 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) today reported operating highlights and financial results for the fourth quarter and year ended December 31, 2015. Recent operational highlights included:

During the fourth quarter, the Company received commitments for the adoption of T2Candida® and the T2Dx® with 11 new hospitals in the United States, including two multi-facility hospital systems of 22 and 14 hospitals, respectively. This brought the total number of commitments to 30 as of December 31, 2015.

BIND Therapeutics and Synergy Pharmaceuticals Announce Collaboration to Develop ACCURINS® with Proprietary Uroguanylin Analogs for Targeting Gastrointestinal Receptors on Tumors

BIND Therapeutics and Synergy Pharmaceuticals Announce Collaboration to Develop ACCURINS® with Proprietary Uroguanylin Analogs for Targeting Gastrointestinal Receptors on Tumors

February 16, 2016

CAMBRIDGE, Mass. & NEW YORK--(BUSINESS WIRE)-- BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine company developing targeted and programmable therapeutics called ACCURINS®, and Synergy Pharmaceuticals Inc.

AZD2811 ACCURINS® Data Published in Science Translational Medicine Highlight One of the First Applications of Nanomedicine to Molecularly Targeted Cancer Therapies

AZD2811 ACCURINS® Data Published in Science Translational Medicine Highlight One of the First Applications of Nanomedicine to Molecularly Targeted Cancer Therapies

February 10, 2016

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine company developing innovative therapeutics called ACCURINS®, today announced the publication of data highlighting the ability of ACCURIN polymeric nanoparticle technology to utilize hydrophobic ion pairing and improve the therapeutic index of a molecularly targeted anti-cancer drug.

Quanterix’s Simoa Technology Demonstrates Ability to Analyze Single Cancer Cells

Quanterix’s Simoa Technology Demonstrates Ability to Analyze Single Cancer Cells

February 10, 2016

LEXINGTON, Mass.--(BUSINESS WIRE)--Quanterix Corporation, a leader in the transformation of healthcare through its ultrasensitive single molecule testing capabilities, today announced that Analytical Chemistry, a leading peer-reviewed scientific journal, has published a truly groundbreaking new study authored by Dr.

Seres Therapeutics Announces Publication of Positive SER-109 Phase 1b/2 Study Results in The Journal of Infectious Diseases

Seres Therapeutics Announces Publication of Positive SER-109 Phase 1b/2 Study Results in The Journal of Infectious Diseases

February 9, 2016

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 9, 2016-- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading microbiome therapeutics company, announced that positive results from the Phase 1b/2 study of SER-109 in recurrent Clostridium Difficile infection (CDI) were published today in The Journal of Infectious Diseases.

Editas Medicine Announces Pricing of Initial Public Offering

Editas Medicine Announces Pricing of Initial Public Offering

February 3, 2016

CAMBRIDGE, Mass., Feb. 02, 2016 (GLOBE NEWSWIRE) -- Editas Medicine, Inc., a leading genome editing company, today announced the pricing of its initial public offering of 5,900,000 shares of common stock at a public offering price of $16.00 per share, before underwriting discounts and commissions. All of the shares are being offered by Editas Medicine.